Thrivent Financial for Lutherans’s Viking Therapeutics VKTX Stock Holding History

Thrivent Financial for Lutherans’s Portfolio VKTX Stock Details VKTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-36,564	Closed	-$969K	–	2618
2025 Q2	$969K	Buy	+36,564	New	+$963K	﹤0.01%	1796
2025 Q1	–	Sell	-27,591	Closed	-$1.11M	–	2557
2024 Q4	$1.11M	Sell	27,591 -660	-2%	-$37.6K	﹤0.01%	1836
2024 Q3	$1.79M	Buy	28,251 +748	+3%	+$43.9K	﹤0.01%	1524
2024 Q2	$1.46M	Buy	27,503 +55	+0.2%	+$3.6K	﹤0.01%	1606
2024 Q1	$2.25M	Buy	+27,448	New	+$1.22M	﹤0.01%	1322
2021 Q1	–	Sell	-11,376	Closed	-$64K	–	2565
2020 Q4	$64K	Hold	11,376	–	–	﹤0.01%	2446
2020 Q3	$66K	Hold	11,376	–	–	﹤0.01%	2353
2020 Q2	$82K	Sell	11,376 -70,005	-86%	-$465K	﹤0.01%	2269
2020 Q1	$381K	Buy	+81,381	New	+$500K	﹤0.01%	1867

Other funds holding VKTX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Thrivent Financial for Lutherans's VKTX Position: Q3 2025 in Review

Thrivent Financial for Lutherans sold out of Viking Therapeutics (VKTX) in Q3 2025, closing a stake of 36,564 shares — an estimated $969K sold.

Thrivent Financial for Lutherans first reported a position in VKTX in Q1 2020 and held it in 9 quarters. The position peaked at $2.25M in Q1 2024. 371 funds tracked by Wall St. Rank hold VKTX as of Q3 2025.

Thrivent Financial for Lutherans reported no remaining Viking Therapeutics position as of Q3 2025 after selling out during the quarter.
Thrivent Financial for Lutherans sold 36,564 Viking Therapeutics shares in Q3 2025, an estimated $969K.
Thrivent Financial for Lutherans first reported a position in Viking Therapeutics in Q1 2020 and held it in 9 quarters.
Thrivent Financial for Lutherans's Viking Therapeutics position peaked at $2.25M in Q1 2024.
371 funds tracked by Wall St. Rank held Viking Therapeutics as of Q3 2025.

Based on Thrivent Financial for Lutherans's 13F filing for Q3 2025, filed 4 Nov 2025.